Neuregulin-1 signaling in the pathogenesis of chemotherapy-induced heart failure

Current Heart Failure Reports

Volumn 11, Issue 2, 2014, Pages 134-138

  Lenneman, Carrie Geisberg ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Breast cancer; Cardiac dysfunction; Cardiomyopathy; Cardiotoxicity; ErbB receptors; Heart failure; Herceptin; Heregulin; Neuregulin; Trastuzumab

Indexed keywords

ANTHRACYCLINE; BIOLOGICAL MARKER; NEU DIFFERENTIATION FACTOR; RECOMBINANT NEUREGULIN 1; RECOMBINANT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NRG1 PROTEIN, HUMAN;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; CHEMOTHERAPY INDUCED HEART FAILURE; HEART DEVELOPMENT; HEART DISEASE; HEART FAILURE; HEART PROTECTION; HUMAN; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARDIOTOXICITY; HEART FAILURE; HUMANS; NEUREGULIN-1; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84903600765     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-014-0193-9     Document Type: Review

References (28)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
2. Pentassuglia L, Sawyer DB. The role of Neuregulin-1 beta/ErbB signaling in the heart. Exp Cell Res. 2009;315:627-37.
3. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386-90.
4. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394-8.
5. Fuller SJ, Sivarajah K, Sugden PH. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol. 2008;44:831-54.
6. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14-30. (Pubitemid 36335807)
7. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378:390-4.
8. Rentschler S, Zander J, Meyers K, et al. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci U S A. 2002;99:10464-9.
9. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459-65. (Pubitemid 34546747)
10. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105:1551-4. (Pubitemid 34297631)
11. Kuramochi Y, Cote GM, Guo XX, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1 beta/erbB4 signaling. J Biol Chem. 2004;279:51141-7. (Pubitemid 40017856)
12. Lebrasseur NK, Cote GM, Miller TA, Fielding RA, Sawyer DB. Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle. Am J Physiol Cell Physiol. 2003;284:C1149-55. (Pubitemid 36457395)
13. Russell KS, Stern DF, Polverini PJ, Bender JR. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol. 1999;277:H2205-11. (Pubitemid 30048139)
14. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279-80. (Pubitemid 34260234)
15. Lange T, Nentwich MF, Luth M, Yekebas E, Schumacher U. Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma. Cancer Lett. 2011;308:54-61.
16. Moondra V, Sarma S, Buxton T, et al. Serum Neuregulin-1beta as a Biomarker of Cardiovascular Fitness. Open Biomark J. 2009;2:1-5.
17. Ky B, Kimmel SE, Safa R, et al. Circulating Neuregulin-1 beta in Human Heart Failure. Circulation. 2009;119:E312-3.
18. • Geisberg CA, Wang G, Safa RN, et al. Circulating neuregulin-1beta levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis. 2011;22:577-82. This small retrospective observational cohort study discovered that plasma NRG-1 inversely correlated with severity of coronary artery disease and that NRG-1 was statisitcally higher in patients with stress tests that were positive for ischemia. The study has led to other work examining the role of NRG-1 as a biomarkerof cardiovascular health.
19. Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114-21. (Pubitemid 47339857)
20. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy ismediated by depletion of the cardiac stemcell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276-92.
21. Peng XY, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanism into preventative medicine. Mol Interv. 2005;5:163-71. (Pubitemid 41018273)
22. Fukazawa R, Miller TA, Kuramochi Y, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol. 2003;35:1473-9. (Pubitemid 37491190)
23. Liu X, Gu X, Li Z, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006;48:1438-47. (Pubitemid 44436803)
24. • Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13:83-92. This was a small singlearm phase I study investigating the safety, tolerability, and hemodynamic effect of a 12-hour infusion of recombinant NRG-1 in stable chronic heart failure patients. The study reveled that this form of recombinant NRG-1 was well-tolerated and produced favorable acute and chronic hemodynamic effects in patients with stable CHF.
25. • Gao R, Zhang J, Cheng L, et al. A Phase II, randomized, doubleblind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55:1907-14. This study demonstrated that in a small randomized control trial of recombinant NRG-1 that a 12 hour infusion for 10-days slightly improved left ventricular ejection fraction and significantly improved ventricular volumes at 90-days suggesting that short-term treatment with rhNRG-1 results in a long-term reversal of remodeling.
26. • Lenihan D, Geisberg C, Caggiano A et al. Safety And Tolerability Of Glial Growth Factor 2 In PatientsWith Chronic Heart Failure: A Phase I Single Dose Escalation Study. JACC 2013;61. This was a phase I single-dose escalation study investigating the safety and tolerability of a 20-minute infusion of a different form of recombinant NRG-1 (Glial Growth Factor, GGF2). The study showed that this form of recombinant NRG-1 was safe and well-tolerated, and showed a trend toward improvement in ventricular ejection fraction at four weeks. Further development of GGF2 as a treatment for systolic heart failure is warranted
27. • Geisberg CA, Abdallah WM, da Silva M, et al. This was a small prospective study of breast cancer patients who underwent serial measurement of cardiac function and biomarkers. More than 20% of women experienced cardiac dysfunction, detected by decline in LVEF, and were reclassified as stage B or C HF. Plasma NRG-1 levels were reduced after exposure to cardiotoxic chemotherapy, suggesting a loss in cardioprotective growth factor. Higher baseline NRG levels were observed in those with the greatest decline in LVEF, supporting the continued investigation of NRG as a potential prognostic marker in early-stage HF. J Card Fail. 2013;19:10-5.
28. Pentassuglia L, Graf M, Lane H, et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res. 2009;315:1302-12.